FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118507153> ?p ?o ?g. }

• W3118507153 endingPage "2199" @default.
• W3118507153 startingPage "2190" @default.
• W3118507153 abstract "Abstract Purpose: TTI-621 (SIRPα-IgG1 Fc) is a novel checkpoint inhibitor that activates antitumor activity by blocking the CD47 “don't eat me” signal. This first-in-human phase I study (NCT02663518) evaluated the safety and activity of TTI-621 in relapsed/refractory (R/R) hematologic malignancies. Patients and Methods: Patients with R/R lymphoma received escalating weekly intravenous TTI-621 to determine the maximum tolerated dose (MTD). During expansion, patients with various malignancies received weekly single-agent TTI-621 at the MTD; TTI-621 was combined with rituximab in patients with B-cell non-Hodgkin lymphoma (B-NHL) or with nivolumab in patients with Hodgkin lymphoma. The primary endpoint was the incidence/severity of adverse events (AEs). Secondary endpoint included overall response rate (ORR). Results: Overall, 164 patients received TTI-621: 18 in escalation and 146 in expansion (rituximab combination, n = 35 and nivolumab combination, n = 4). On the basis of transient grade 4 thrombocytopenia, the MTD was determined as 0.2 mg/kg; 0.1 mg/kg was evaluated in combination cohorts. AEs included infusion-related reactions, thrombocytopenia, chills, and fatigue. Thrombocytopenia (20%, grade ≥3) was reversible between doses and not associated with bleeding. Transient thrombocytopenia that determined the initial MTD may not have been dose limiting. The ORR for all patients was 13%. The ORR was 29% (2/7) for diffuse large B-cell lymphoma (DLBCL) and 25% (8/32) for T-cell NHL (T-NHL) with TTI-621 monotherapy and was 21% (5/24) for DLBCL with TTI-621 plus rituximab. Further dose optimization is ongoing. Conclusions: TTI-621 was well-tolerated and demonstrated activity as monotherapy in patients with R/R B-NHL and T-NHL and combined with rituximab in patients with R/R B-NHL." @default.
• W3118507153 created "2021-01-18" @default.
• W3118507153 creator A5002126535 @default.
• W3118507153 creator A5008086243 @default.
• W3118507153 creator A5011559739 @default.
• W3118507153 creator A5012174657 @default.
• W3118507153 creator A5012279318 @default.
• W3118507153 creator A5013307217 @default.
• W3118507153 creator A5017873196 @default.
• W3118507153 creator A5020092189 @default.
• W3118507153 creator A5021957877 @default.
• W3118507153 creator A5022743718 @default.
• W3118507153 creator A5026397928 @default.
• W3118507153 creator A5031662456 @default.
• W3118507153 creator A5032617342 @default.
• W3118507153 creator A5033794128 @default.
• W3118507153 creator A5035051206 @default.
• W3118507153 creator A5045731423 @default.
• W3118507153 creator A5054420141 @default.
• W3118507153 creator A5056912326 @default.
• W3118507153 creator A5059729547 @default.
• W3118507153 creator A5063781871 @default.
• W3118507153 creator A5069406522 @default.
• W3118507153 creator A5070507875 @default.
• W3118507153 creator A5074136068 @default.
• W3118507153 creator A5080209757 @default.
• W3118507153 creator A5082944296 @default.
• W3118507153 creator A5086142649 @default.
• W3118507153 date "2021-01-15" @default.
• W3118507153 modified "2023-10-17" @default.
• W3118507153 title "Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies" @default.
• W3118507153 cites W1966217032 @default.
• W3118507153 cites W1991656907 @default.
• W3118507153 cites W2001570963 @default.
• W3118507153 cites W2038795176 @default.
• W3118507153 cites W2044436186 @default.
• W3118507153 cites W2089881927 @default.
• W3118507153 cites W2092246736 @default.
• W3118507153 cites W2096850086 @default.
• W3118507153 cites W2097126393 @default.
• W3118507153 cites W2103746815 @default.
• W3118507153 cites W2119147717 @default.
• W3118507153 cites W2126448969 @default.
• W3118507153 cites W2130869560 @default.
• W3118507153 cites W2142099365 @default.
• W3118507153 cites W2144945558 @default.
• W3118507153 cites W2159507916 @default.
• W3118507153 cites W2514468425 @default.
• W3118507153 cites W2550646651 @default.
• W3118507153 cites W2765435137 @default.
• W3118507153 cites W2784099979 @default.
• W3118507153 cites W2795318100 @default.
• W3118507153 cites W2890786500 @default.
• W3118507153 cites W2899044337 @default.
• W3118507153 cites W2907227169 @default.
• W3118507153 cites W2936913202 @default.
• W3118507153 cites W2947092073 @default.
• W3118507153 cites W3095354231 @default.
• W3118507153 cites W4376595466 @default.
• W3118507153 doi "https://doi.org/10.1158/1078-0432.ccr-20-3706" @default.
• W3118507153 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33451977" @default.
• W3118507153 hasPublicationYear "2021" @default.
• W3118507153 type Work @default.
• W3118507153 sameAs 3118507153 @default.
• W3118507153 citedByCount "91" @default.
• W3118507153 countsByYear W31185071532021 @default.
• W3118507153 countsByYear W31185071532022 @default.
• W3118507153 countsByYear W31185071532023 @default.
• W3118507153 crossrefType "journal-article" @default.
• W3118507153 hasAuthorship W3118507153A5002126535 @default.
• W3118507153 hasAuthorship W3118507153A5008086243 @default.
• W3118507153 hasAuthorship W3118507153A5011559739 @default.
• W3118507153 hasAuthorship W3118507153A5012174657 @default.
• W3118507153 hasAuthorship W3118507153A5012279318 @default.
• W3118507153 hasAuthorship W3118507153A5013307217 @default.
• W3118507153 hasAuthorship W3118507153A5017873196 @default.
• W3118507153 hasAuthorship W3118507153A5020092189 @default.
• W3118507153 hasAuthorship W3118507153A5021957877 @default.
• W3118507153 hasAuthorship W3118507153A5022743718 @default.
• W3118507153 hasAuthorship W3118507153A5026397928 @default.
• W3118507153 hasAuthorship W3118507153A5031662456 @default.
• W3118507153 hasAuthorship W3118507153A5032617342 @default.
• W3118507153 hasAuthorship W3118507153A5033794128 @default.
• W3118507153 hasAuthorship W3118507153A5035051206 @default.
• W3118507153 hasAuthorship W3118507153A5045731423 @default.
• W3118507153 hasAuthorship W3118507153A5054420141 @default.
• W3118507153 hasAuthorship W3118507153A5056912326 @default.
• W3118507153 hasAuthorship W3118507153A5059729547 @default.
• W3118507153 hasAuthorship W3118507153A5063781871 @default.
• W3118507153 hasAuthorship W3118507153A5069406522 @default.
• W3118507153 hasAuthorship W3118507153A5070507875 @default.
• W3118507153 hasAuthorship W3118507153A5074136068 @default.
• W3118507153 hasAuthorship W3118507153A5080209757 @default.
• W3118507153 hasAuthorship W3118507153A5082944296 @default.
• W3118507153 hasAuthorship W3118507153A5086142649 @default.
• W3118507153 hasBestOaLocation W31185071531 @default.
• W3118507153 hasConcept C121332964 @default.
• W3118507153 hasConcept C121608353 @default.

• next